Published in Br J Rheumatol on August 01, 1989
Diffuse idiopathic skeletal hyperostosis and its relation to back pain among older men: the MrOS Study. Semin Arthritis Rheum (2011) 1.22
Diffuse idiopathic skeletal hyperostosis: clinical features and pathogenic mechanisms. Nat Rev Rheumatol (2013) 1.10
Diffuse idiopathic skeletal hyperostosis in ancient clergymen. Eur Spine J (2007) 0.89
Diffuse idiopathic skeletal hyperostosis (DISH) of the elbow: a controlled radiological study. BMC Musculoskelet Disord (2015) 0.80
Bone: Exploring factors responsible for bone formation in DISH. Nat Rev Rheumatol (2011) 0.77
Chiropractic management of a veteran with lower back pain associated with diffuse idiopathic skeletal hypertrophy and degenerative disk disease. J Chiropr Med (2012) 0.76
Back pain in the older patient. Ann Rheum Dis (1996) 0.75
Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. RMD Open (2017) 0.75
Diffuse Idiopathic Skeletal Hyperostosis (DISH) and Impaired Physical Function: The Rancho Bernardo Study. J Am Geriatr Soc (2017) 0.75
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet (1997) 6.71
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol (1996) 2.90
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis (2004) 2.08
Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage. Arthritis Rheum (2002) 1.87
Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (2001) 1.86
How Renoir coped with rheumatoid arthritis. BMJ (1998) 1.84
Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis (2001) 1.77
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
A brief history of spa therapy. Ann Rheum Dis (2002) 1.67
Can exercise prevent osteoporosis? Br J Rheumatol (1991) 1.59
Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis (2005) 1.59
Development of a questionnaire to investigate patient compliance with antirheumatic drug therapy. J Rheumatol (1999) 1.54
Graves' ophthalmopathy: natural history and treatment outcomes. Swiss Med Wkly (2001) 1.52
[Various opinions of family physicians and rheumatologists about the management of patients with rheumatoid arthritis]. Ned Tijdschr Geneeskd (1996) 1.52
Comparing morphometric X-ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatology (Oxford) (2007) 1.49
Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis (2004) 1.49
Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis (2008) 1.44
Detection of flexor tenosynovitis by magnetic resonance imaging: its relationship to diurnal variation of symptoms. J Rheumatol (1991) 1.40
Lymphocytic and granulomatous hypophysitis: experience with nine cases. Neurosurgery (1999) 1.40
A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol (1999) 1.40
Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis (2001) 1.38
The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a family and population study. Br J Rheumatol (1983) 1.37
Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol (1999) 1.36
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol (1999) 1.31
Developing case-specific checklists for standardized-patient-based assessments in internal medicine: A review of the literature. Acad Med (2000) 1.30
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.29
Comparison between self-report measures and clinical observations of functional disability in ankylosing spondylitis, rheumatoid arthritis and fibromyalgia. J Rheumatol (1994) 1.29
Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV. J Rheumatol (1999) 1.28
Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 1.26
The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum (2006) 1.25
Knee effusion and reflex inhibition of the quadriceps. A bar to effective retraining. J Bone Joint Surg Br (1988) 1.23
Popliteal cysts and synovial rupture in osteoarthrosis. Rheumatol Rehabil (1974) 1.21
Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology (Oxford) (2005) 1.18
Joint consultation of general practitioner and rheumatologist: does it matter? Ann Rheum Dis (2003) 1.17
Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis (2005) 1.15
Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis (2006) 1.11
Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol (2001) 1.11
Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol (1995) 1.10
Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum (2001) 1.09
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis (2004) 1.07
Yttrium radiosynoviorthesis in the treatment of knee arthritis in rheumatoid arthritis: a systematic review. Ann Rheum Dis (2000) 1.06
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis (2006) 1.02
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01
Urinary iodine concentration during pregnancy in an area of unstable dietary iodine intake in Switzerland. J Endocrinol Invest (2003) 1.01
Feasibility of utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia. J Rheumatol (1994) 1.01
Swollen lower extremity: role of MR imaging. Radiology (1992) 1.01
Therapeutic effects of individual physical therapy in ankylosing spondylitis related to duration of disease. Clin Rheumatol (1993) 1.00
Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid (2001) 1.00
Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr (1994) 1.00
Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 0.99
Psoriatic arthritis: performance of rheumatologists in daily practice. Ann Rheum Dis (2002) 0.99
Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (1992) 0.97
Serum IgA, acute phase proteins, and glycosylation of alpha 1-acid glycoprotein in ankylosing spondylitis. Ann Rheum Dis (1989) 0.97
Pericarditis after therapy with interferon-alpha for chronic hepatitis C. Clin Rheumatol (1999) 0.97
Physical activity and body composition in patients with ankylosing spondylitis. Arthritis Care Res (Hoboken) (2012) 0.96
Rhemulatologists' performance in dailiy practice. Arthritis Rheum (2001) 0.94
Care of burns victims in Europe. Burns (1999) 0.94
Work factors and behavioural coping in relation to withdrawal from the labour force in patients with rheumatoid arthritis. Ann Rheum Dis (2001) 0.94
Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol (1994) 0.93
Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. Ann Rheum Dis (2002) 0.93
[Topographic x-ray anatomy of inguinal and retroperitoneal lymph nodes]. Radiologe (1970) 0.93
[On the pathology and genetics of the basal cell-nevus syndrome]. Humangenetik (1965) 0.93
Blockade of glucocorticoid receptors rapidly restores hippocampal CA1 synaptic plasticity after exposure to chronic stress. Eur J Neurosci (2006) 0.93
Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) (2008) 0.93
Thymoma-associated systemic lupus erythematosus, exacerbating after thymectomy. A case report and review of the literature. Rheumatology (Oxford) (2000) 0.93
Lymphography in carcinoma of the prostate. Br J Urol (1974) 0.92
Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol (1997) 0.92
High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis. J Rheumatol (2001) 0.91
Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis (2004) 0.89
Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol (2001) 0.89
[Clinico-radiographic tests of the new, soluble in water, tri-iodized contrast medium Uromiro]. Praxis (1966) 0.89
Computed tomography in carcinoma of the rectum. Gastrointest Radiol (1981) 0.88
Spondylarthropathies: options for combination therapy. Springer Semin Immunopathol (2001) 0.88
Methodological issues of patient utility measurement. Experience from two clinical trials. Med Care (1995) 0.87
Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol (1996) 0.87
Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. J Rheumatol (1995) 0.86
Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol (1996) 0.86
Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res (1993) 0.86
Pelvic manifestations of diffuse idiopathic skeletal hyperostosis (DISH): are they clinically relevant? Rheumatol Int (1989) 0.85
Dissociation between apoptosis, neurogenesis, and synaptic potentiation in the dentate gyrus of adrenalectomized rats. Synapse (2007) 0.85
Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis (1994) 0.85
Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res (1994) 0.84
MRI and sonography of the shoulder. Clin Radiol (1991) 0.84
Definition of disease duration in ankylosing spondylitis: reassessing the concept. Ann Rheum Dis (2006) 0.84
Health related utility measurement: an introduction. J Rheumatol (1995) 0.84